Compare ENRD & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENRD | YDES |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Sweden | Taiwan |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 476.8M |
| IPO Year | 2025 | 2024 |
| Metric | ENRD | YDES |
|---|---|---|
| Price | $2.50 | $6.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 194.0K | ★ 502.7K |
| Earning Date | 11-24-2026 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $40.92 | N/A |
| Revenue Next Year | $205.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.66 | $1.70 |
| 52 Week High | $10.49 | $22.00 |
| Indicator | ENRD | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 23.95 | 56.05 |
| Support Level | N/A | $2.33 |
| Resistance Level | $4.38 | $8.89 |
| Average True Range (ATR) | 0.32 | 1.16 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 3.48 | 43.85 |
Einride AB is a technology company that develops and operates digital, electric, and autonomous freight solutions. Its platform includes planning and optimization tools, autonomous technologies, electric heavy-duty vehicle fleets, and charging infrastructure. It serves customers across North America, Europe, and the Middle East. The company's solutions support customers in transitioning logistics operations to electric and autonomous systems. Its business model includes Freight-Capacity-as-a-Service (FCaaS) and Software-as-a-Service (SaaS) offerings delivered through an AI-based platform that manages aspects of electric and autonomous operations.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.